Overview of Téralithe LP

Quick Facts

Property	Description
Active ingredient	Lithium carbonate
Form	Prolonged-release tablets (Sustained-release)
Pharmacological class	Psychotropic agent, Mood stabilizer (Thymoregulator)
Common use	Providing neurological stability to balance mood
Origin	Inorganic salt (Essential trace element)

Téralithe LP: Definition and Pharmacological Classification

Téralithe LP is a prescription-only medicine classified as a psychotropic agent and an antimanic agent within the Anatomical Therapeutic Chemical (ATC) classification system. Its active component is Lithium carbonate, an inorganic salt used for systemic action on the central nervous system. The core chemical entity, Lithium, is an essential trace element that functions biologically as a monovalent cation. Clinical practice recognizes lithium compounds as a foundational treatment for long-term neurological stability.

Why Téralithe LP Uses a Prolonged-Release Formulation

The "LP" designation in Téralithe LP signifies a prolonged-release tablet, which is a specialized sustained-release dosage form designed for controlled delivery. This formulation ensures the Lithium carbonate is released slowly and steadily over many hours following oral administration. This unique controlled release mechanism is intended to maintain stable, consistent blood levels of Lithium; this steady state is utilized for achieving its thymoregulatory effects. These prolonged-release formulations provide similar efficacy to immediate-release forms and are intended to offer superior tolerability, particularly in reducing tremors often associated with high peak concentrations.

General Purpose of this Mood Stabilizer Class

The primary role of this medicine is to provide foundational neurological equilibrium by regulating nerve cell activity. As a mood stabilizer and thymoregulator, the drug works by influencing chemical signals in the brain, helping to stabilize and smooth out severe physiological extremes associated with emotional and energy fluctuations. A typical application is for patients who require consistent psychological stabilization, such as maintaining a regulated baseline of mood and energy over extended periods. This function serves to support a more predictable psychological state.

Regulatory References

supported by the National Institutes of Health

What side effects are possible with Téralithe LP?

Téralithe LP: Possible Side Effects and Safety Information

The medicine's safety profile is intrinsically tied to its serum concentration, with Lithium Toxicity possible at levels near the therapeutic range, making close observation a foundational regulatory requirement. Adverse reactions that may appear during initial therapy and sometimes persist throughout treatment include fine hand tremor, polyuria (excessive urination), mild thirst, and nausea.

Adverse Reactions by System-Organ Class

Official regulatory documentation groups potential effects across several major systems. Nervous System effects may include ataxia, confusion, and dizziness. The Renal and Urinary System is affected by polyuria and polydipsia, and long-term exposure is associated with structural changes such as Lithium-Induced Chronic Kidney Disease. Effects on the Endocrine System include changes in thyroid function (hypothyroidism) and documented risks of Hypercalcemia.

Serious Adverse Reactions and Restrictions

Several severe reactions are explicitly listed in regulatory labeling. These include the risk of Serotonin Syndrome (when combined with serotonergic agents) and a serious neurological event known as Encephalopathic Syndrome. The label also notes the risk of Unmasking of Brugada Syndrome, a documented cardiac disorder. Use is restricted in patients with significant renal or cardiovascular disease, severe dehydration, or sodium depletion. Fetal harm is a specific consideration, with a documented association with cardiac anomalies (e.g., Ebstein's anomaly), necessitating explicit safety statements for pregnancy and geriatric patients.

Overdose and Emergency Response

The official regulatory documents define the overdose profile of Téralithe LP (Lithium Carbonate) based on observable clinical signs of toxicity and mandated emergency responses.

Manifestation Profile	Regulator-Mandated Action
Mild to Moderate: Fine to coarse tremor, slurred speech, mild ataxia, nausea, and diarrhea.	Patient must discontinue Téralithe LP and contact their physician immediately if these signs occur.
Severe/Life-Threatening: Convulsions, confusion, coma, abnormal heart beats, or shortness of breath.	Seek immediate emergency assistance or call 911 for these severe symptoms.

The toxicity risk is significantly elevated when serum lithium levels exceed 1.5 mEq/L, or in patients experiencing dehydration, sodium depletion, or with significant renal or cardiovascular disease. Severe toxicity may lead to renal failure or irreversible neurological damage. Elderly patients are also at increased risk due to age-related renal changes.

Overdose management requires hospital monitoring, including cardiac evaluation and serial measurements of serum lithium levels until a descending trend is confirmed. No specific antidote for lithium poisoning is known. Treatment procedures focus on elimination, often requiring hemodialysis in severe cases.

Therapeutic Uses of Téralithe LP

Téralithe LP (lithium carbonate) is a key component used to help stabilize mood in certain categories of mood disorders. This extended-release medication is indicated to help manage symptoms during acute manic or mixed episodes of Bipolar I Disorder. It is also prescribed as a long-term maintenance treatment to help prevent the return of manic and depressive episodes in patients with Bipolar Disorder. By assisting with mood regulation, Téralithe LP supports patients in managing extreme shifts in emotion, which may help maintain stability in daily activities and improve overall emotional balance.

Quick Fact: Relief for Mood Instability Téralithe LP is used as part of the overall management plan for mood disorders, working to reduce the frequency and intensity of episodes.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Téralithe LP

This section outlines populations, conditions, and states for whom the use of Téralithe LP (lithium carbonate) is formally restricted or prohibited, based strictly on official regulatory labeling.

Populations for Whom Use is Prohibited (Contraindications)

Téralithe LP is formally contraindicated in individuals with:

Hypersensitivity to lithium carbonate or any of the inactive ingredients.
Severe renal impairment or severe renal insufficiency.
Cardiac insufficiency or cardiac disease associated with rhythm disorder.
Untreated hypothyroidism.
Addison's disease.
States of low body sodium levels (e.g., dehydration, low-sodium diets).
Brugada syndrome or a family history of Brugada syndrome.
Women who are breast-feeding (lactation).

Use Restrictions and Special Considerations

Use is generally not recommended or requires special caution for:

Pediatric patients under 12 years of age, as safety and effectiveness have not been established.
Patients with mild to moderate renal impairment, where close and regular monitoring of lithium and creatinine levels is not possible.
Older adults (geriatric patients) are more susceptible to toxicity and typically require lower starting doses and closer monitoring of kidney function.

Regulatory documents emphasize that patients abnormally sensitive to lithium may show signs of toxicity even at concentrations usually considered therapeutic.

What should I know about interactions with other medicines?

The official regulatory profile for Téralithe LP (Lithium carbonate) details clinically significant interactions driven by both pharmacokinetic and pharmacodynamic mechanisms.

Interaction Classification	Official Regulatory Statement
Exposure-Increasing	Diuretics, NSAIDs, ACE inhibitors, and Metronidazole are officially documented to reduce the renal clearance of lithium, leading to increased serum concentrations.
Exposure-Decreasing	Acetazolamide, Theophylline, and high sodium intake are officially documented to increase urinary excretion of lithium, potentially causing a loss of efficacy.
Pharmacodynamic Risk	Co-administration with serotonergic agents ( SSRIs, St. John's Wort) increases the risk of Serotonin Syndrome. Antipsychotic drugs are linked to a risk of neurotoxicity.
Interaction Restriction	The combination with diuretics is contraindicated in patients with severe renal or cardiovascular disease, dehydration, or sodium depletion due to the high risk of lithium toxicity.
Population Notes	Elderly patients and those with impaired renal function have a heightened interaction risk because of reduced lithium clearance.

The officially defined structure of lithium interactions centers on its renal elimination and sodium balance. Co-administered agents that affect sodium homeostasis or renal blood flow are the major source of pharmacokinetic risk, directly affecting lithium exposure. This regulatory profile confirms that lithium interactions are classified as Clinically Significant, requiring careful monitoring of serum concentration when initiating or discontinuing an interacting medicine. No timing-based separation rules are documented; the focus is on systemic exposure management.

Mechanism of Action

️ How Téralithe LP Works

Modulating Intracellular Enzyme Systems and Signaling

The drug functions by directly inhibiting key enzymes, primarily Glycogen Synthase Kinase-3 (GSK-3) and Inositol Monophosphatase (IMPase), within the central nervous system. This molecular action disrupts the phosphatidylinositol (PI) signaling cascade, which functionally modulates overactive neuronal signaling and limits excessive cellular responsiveness by restricting the production of crucial second messengers.

Enhancing Neuroplasticity and Promoting Neuronal Health

The inhibition of GSK-3 initiates a cascade that leads to the stabilization of key proteins, promoting the gene expression of neurotrophic factors like BDNF (Brain-Derived Neurotrophic Factor). This mechanism supports neuroprotection and enhances neuroplasticity, contributing to the structural stability of nerve cells through cytoskeletal regulation.

Stabilizing Neuronal Membrane Excitability

Téralithe LP acts as a monovalent cation that influences cellular transport systems by competing with sodium ions (Na+) for passage across the neuronal membrane. This interaction functionally alters ion flow, leading to a direct stabilizing effect on neuronal excitability that raises the threshold for firing and modulates the frequency of hyperexcitable discharges, which contributes to establishing a regulated physiological baseline of nerve cell activity.

Dosage and Administration Information

How to use Téralithe LP — Administration Guidelines

Téralithe LP is an oral, extended-release tablet for daily use. Adherence to the prescribed regimen and strict monitoring of blood concentration are essential components of its administration.

Administration Protocol

Feature	Instruction
Route of Administration	Oral
Form	Extended-release (LP) tablet. The tablet is scored and can be broken into two halves.
Preparation	Tablets must be swallowed whole with a glass of water. They must not be chewed, crushed, or sucked.
Timing and Frequency	Taken once daily, preferably during the evening meal (around 8 PM).
Food and Drink	Take the dose with the evening meal. Do not make sudden changes to your sodium (salt) intake in your diet; a salt-free diet is strictly prohibited.

Dosing and Monitoring Requirements

Rule	Procedural Step
Dosing Rule	The dosage is individualized based on the patient's clinical response and measured blood lithium concentrations (lithiémie).
Target Concentration	The dose is adjusted to maintain the lowest effective plasma concentration (Cmin) for maintenance therapy, typically between 0.5 to 0.8 mEq/L (or mmol/L).
Blood Testing	Regular monitoring of lithium levels. Blood tests are typically performed 12 hours after the evening dose to ensure consistent results and safe levels.
Dose Adjustment	If blood levels are insufficient, the dose is increased in small increments, often by a half-tablet, under the supervision of a physician.
Elderly Patients	Initial and maintenance doses must be lower and increased more gradually due to potentially decreased lithium excretion.
Discontinuation	Treatment must not be stopped abruptly without consulting the prescribing physician.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Téralithe LP

Evidence for Use in Acute Manic and Mixed Episodes

Téralithe LP (lithium carbonate) was studied for use during periods of heightened symptom activity associated with Bipolar Disorder. The core research relies on short-term, placebo-controlled Randomized Controlled Trials (RCTs) that examined short-term symptom changes in patients. Researchers monitored and measured specific outcomes capturing phases of heightened symptom activity, using standardized rating scales over observation periods of a few weeks up to approximately eight weeks. The data describe patterns related to measured outcomes in symptoms when compared to placebo groups. However, the initial follow-up durations were limited to the acute phase, and these studies provide limited direct insight into longer-term effects.

Evidence for Use as Long-Term Maintenance Treatment

For the long-term management of Bipolar Disorder, research was evaluated in patients to explore outcomes related to the recurrence of mood episodes. This involves long-term RCTs where patients who had already reached stability were randomly assigned to either continue on lithium or switch to a placebo. Additionally, long-term prospective and retrospective observational studies research examined patient outcomes over periods lasting years. The main outcomes monitored were the time to recurrence of a new mood episode (specifically manic, hypomanic, or depressive) and overall rates of hospitalization.

Findings from these long-term studies describe patterns observed in the studies related to time to recurrence for manic and hypomanic episodes. The aggregated evidence reports consistent patterns in the observed outcomes when compared to placebo groups in the studies. However, research highlights changes measured during the study period for the time to recurrence for depressive relapses were often documented as less clear or findings were mixed across different trials. These epidemiological studies also contribute to the broader evidence landscape by describing an observed pattern related to suicidal ideation/behavior outcomes in certain treated cohorts.

What Research Limitations and Gaps Remain

Scientific review highlights several areas where the research landscape is not complete. One key limitation is the heterogeneity (variability) in patient populations and designs across many older, foundational maintenance trials. Specifically, while the patterns related to time to recurrence for manic episodes are widely documented, the findings related to time to recurrence for depressive relapses are documented as less robust than the data related to time to recurrence for manic relapses. Additionally, there is limited information for long-term outcomes when comparing lithium head-to-head with many of the newer psychotropic medicines used for mood stabilization.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Téralithe LP (FAQ)

Q: Does Téralithe LP cause weight gain?

A: Official documentation for lithium products indicates that weight gain has been reported as a documented side effect during treatment. This is considered an effect on the metabolic system. Concerns about changes in weight are typically a matter for discussion with a healthcare provider to explore monitoring options.

Q: Can Téralithe LP make you feel tired or drowsy?

A: Yes, official safety information describes effects on the central nervous system, which may include feeling drowsy (somnolence) and fatigue. These reactions are possible side effects of the medication. Official warnings state that the ability to drive or operate complex machinery may be impaired if these effects are experienced.

Q: Can Téralithe LP be taken by people with thyroid problems?

A: While untreated hypothyroidism is a formal contraindication, official precautions state that people with other pre-existing thyroid disorders may still receive treatment. However, careful and regular monitoring of thyroid function is necessary during stabilization and maintenance therapy. Close monitoring helps in observing any changes in thyroid parameters that might occur during treatment.

Q: What is the difference between Téralithe LP and Téralithe (non-LP)?

A: Téralithe LP is an extended-release (LP) tablet, which is specially formulated to release the medication slowly and steadily over many hours. This controlled-release design aims to achieve lower peak concentrations of lithium in the blood compared to conventional, immediate-release (non-LP) forms. Lower peak concentrations may affect the overall tolerability of the medicine.

Q: Are there any specific safety warnings for women of childbearing age taking Téralithe LP?

A: Regulatory documents indicate that information about the potential hazard to the developing fetus should be communicated to patients if use during pregnancy is considered. This includes a documented association between lithium exposure during pregnancy and an increased risk of certain cardiac anomalies, such as Ebstein's anomaly.

Q: Is there a risk of dependence or withdrawal with Téralithe LP?

A: Official administration rules strongly emphasize that treatment must not be stopped abruptly without consultation with the prescribing physician. The regulatory text does not use the specific terms 'dependence' or 'withdrawal,' but the warning against sudden discontinuation indicates the potential for adverse effects upon cessation.

Q: How does Téralithe LP affect salt levels in the body?

A: Official regulatory warnings explain that lithium can affect the kidneys’ ability to manage sodium (salt) levels in the body. It may decrease sodium reabsorption, potentially leading to sodium depletion. For this reason, maintaining a normal, consistent diet—including adequate salt and fluid intake—is often noted as important for managing lithium levels.

Q: Is it possible to take Téralithe LP and still drink alcohol?

A: Official regulatory warnings indicate that alcohol may increase certain side effects of lithium on the nervous system. These combined effects can result in increased dizziness, drowsiness, and difficulty concentrating. Discussions regarding the use of alcohol during treatment are typically conducted with a healthcare provider.

Q: Is Téralithe LP the same as other forms of Lithium?

A: Téralithe LP contains the active ingredient Lithium carbonate. This is one of the available forms of lithium medication. Other forms, such as Lithium citrate liquid, are also available but are formulated differently and may have distinct dosing and administration considerations.

Q: What happens if I miss a dose of Téralithe LP?

A: Official guidance advises patients not to double a dose if one is missed to make up for the omission. For management of a missed dose, consultation with the prescribing physician or healthcare provider is the established procedure. Do not attempt to make your own adjustments to the dosing schedule.

Q: Is Téralithe LP known to interact with caffeine?

A: Official warnings note that substances with diuretic properties, such as caffeine, may increase the urinary excretion of lithium. Significant or sudden changes in intake of diuretics like caffeine are recognized in the regulatory literature as potentially affecting lithium exposure and maintenance of therapeutic levels.

Q: Can Téralithe LP cause changes in my skin or hair?

A: Yes, official documentation reports that effects on the skin and hair have been observed with lithium use. These documented adverse events include a skin rash resembling acne and hair thinning or hair loss (alopecia). These are listed among the potential adverse reactions.

Q: Is Téralithe LP a controlled substance?

A: According to the official product labeling and the U.S. Drug Enforcement Administration (DEA) Schedule, lithium carbonate is not classified as a controlled substance.

Q: Does Téralithe LP interact with cold or flu medications?

A: Many common cold and flu medications contain ingredients that have documented interactions with lithium. For example, some may contain NSAIDs, which can increase lithium levels, or ingredients like dextromethorphan or doxylamine, which can increase nervous system side effects. Reviewing the ingredients of any over-the-counter medicine with a healthcare provider is generally recommended.

Q: Are there different strengths of Téralithe LP available?

A: Official labeling confirms that extended-release (LP) tablets of lithium carbonate are available in multiple strengths. The 'How Supplied' sections of official documents often list tablets in strengths such as 300 mg and 450 mg.

Q: Is it normal to have stomach upset when first starting Téralithe LP?

A: The official safety profile lists several common gastrointestinal side effects that may appear during initial therapy with lithium. These include nausea and diarrhea. These reactions are frequently noted when a patient first begins taking the medication and may diminish over time.

Q: Is Téralithe LP a generic or brand-name drug?

A: Téralithe LP is the brand name for this specific extended-release medication. The active ingredient it contains is Lithium carbonate, which is the internationally recognized generic name for the drug substance.

Q: Are there any specific warnings for people with diabetes taking Téralithe LP?

A: Official precautions indicate that lithium may potentially interfere with the therapeutic effects of insulin and other antidiabetic agents. Regulatory documents state that when lithium is co-administered with antidiabetic agents, closer monitoring of blood glucose levels may be required by the physician.

How should Téralithe LP be stored and disposed of?

Storage and Handling Requirements

Official labeling for Téralithe LP (lithium carbonate prolonged-release tablets) indicates no particular storage precautions are required for the unopened product. To ensure product stability, the medication must not be used after the expiry date marked on the packaging. As with all prescription drugs, Téralithe LP must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal of Unused Medicine

Téralithe LP must be disposed of in a manner that protects the environment. The medicine must not be thrown into wastewater or household garbage. Patients are instructed to return unused or expired tablets to a pharmacist for proper pharmaceutical waste disposal, according to local regulations.

Téralithe LP